Dr. Stephen Grubbs

Oncology
Christiana Care Health Services Inc.
4701 Ogletown Stanton Rd, 
Newark, DE 
Christiana Care Health Services Inc.
4701 Ogletown Stanton Rd, 
Newark, DE 

Overview

Stephen Grubbs is an Oncologist practicing medicine in Newark, Delaware.

His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, and Breast Cancer.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in DE

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO

Locations

Christiana Care Health Services Inc.
4701 Ogletown Stanton Rd, Newark, DE 19713

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 4 Less Clinical Trials

22 Total Publications

The development of national learning collaborative for ePRO enabled RSM in oncology: insights for co-implementation.
The development of national learning collaborative for ePRO enabled RSM in oncology: insights for co-implementation.
Journal: Implementation science communications
Published: September 09, 2025
Similar Doctors
Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology
Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (31.2 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
14
conditions
Dr. Corey J. Langer
Oncology
Expertise in
14
conditions
Dr. Corey J. Langer
Oncology
Referral may be required

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (31.2 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is board certified in Medical Oncology, 1987, Hematology, 1986, and Internal Medicine, 1984. Dr. Langer is currently accepting new patients.

Expertise in
14
conditions
Dr. Janet Kwiatkowski
Hematology | Oncology
Expertise in
14
conditions
Dr. Janet Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (31.2 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Frequently Asked Questions about Dr. Stephen Grubbs

How do I make an appointment with Dr. Stephen Grubbs?

You can book an appointment with Dr. Stephen Grubbs by calling their office at 302-366-1200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen Grubbs a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen Grubbs is classified as an Experienced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen Grubbs specialize in?

While Dr. Stephen Grubbs is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Stephen Grubbs participate in research or clinical trials?

Yes. Dr. Stephen Grubbs has published 22 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Stephen Grubbs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen Grubbs accept my insurance?

Dr. Stephen Grubbs accepts most major insurance plans, including CareFirst and Highmark. We recommend calling the office directly at 302-366-1200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grubbs's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile